Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
4(40%)
Results Posted
0%(0 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_1
8
80%
Ph phase_2
2
20%

Phase Distribution

8

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
8(80.0%)
Phase 2Efficacy & side effects
2(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(3)
Terminated(3)

Detailed Status

Completed3
Terminated3
Active, not recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (80.0%)
Phase 22 (20.0%)

Trials by Status

completed330%
terminated330%
active_not_recruiting220%
recruiting220%

Recent Activity

4 active trials
Showing 5 of 10
active_not_recruitingphase_1

QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

NCT07708272
active_not_recruitingphase_1

Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets

NCT07608666
terminatedphase_1

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

NCT04941404
completedphase_2

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

NCT05020652
terminatedphase_1

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

NCT06245941
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07708272Phase 1

QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

Active Not Recruiting
NCT07608666Phase 1

Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets

Active Not Recruiting
NCT04941404Phase 1

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

Terminated
NCT05020652Phase 2

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Completed
NCT06245941Phase 1

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Terminated
NCT06024915Phase 1

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Completed
NCT06122831Phase 1

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

Recruiting
NCT06388759Phase 1

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Terminated
NCT06300320Phase 2

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Recruiting
NCT05982106Phase 1

To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10